Cargando…

Topical Insights Into the Post-Approval Controversies of Aducanumab

Detalles Bibliográficos
Autores principales:	Kumar, Dhiraj, Yadav, Dharmendra Kumar, Hassan, Md Imtaiyaz
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2021
Materias:	Pharmacology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8637044/ https://www.ncbi.nlm.nih.gov/pubmed/34867420 http://dx.doi.org/10.3389/fphar.2021.787303

Ejemplares similares

An insider's perspective on FDA approval of aducanumab
por: Wang, Yaning
Publicado: (2023)

How Will Aducanumab Approval Impact AD Research?
por: Weiner, Michael W., et al.
Publicado: (2021)

Aducanumab: evidence from clinical trial data and controversies
por: Tampi, Rajesh R, et al.
Publicado: (2021)

Consensus Statement Regarding the Application of Biogen to Health Canada for Approval of Aducanumab
por: Chertkow, Howard, et al.
Publicado: (2021)

Aducanumab as a Novel Treatment for Alzheimer’s Disease: A Decade of Hope, Controversies, and the Future
por: Esang, Michael, et al.
Publicado: (2021)

Avoiding future controversies in the Alzheimer’s disease space through understanding the aducanumab data and FDA review
por: Dickson, Samuel P., et al.
Publicado: (2023)

Aducanumab for Alzheimer’s disease?
por: Walsh, Sebastian, et al.
Publicado: (2021)

Knowledge and Attitudes Concerning Aducanumab Among Older Americans After FDA Approval for Treatment of Alzheimer Disease
por: Zissimopoulos, Julie, et al.
Publicado: (2022)

Insight Into the Molecular Dynamic Simulation Studies of Reactive Oxygen Species in Native Skin Membrane
por: Yadav, Dharmendra K., et al.
Publicado: (2018)

Aducanumab: What about the Patient?
por: Petersen, Ronald C.
Publicado: (2021)

Is Aducanumab for LMICs? Promises and Challenges
por: Gunawardena, Illangage P. C., et al.
Publicado: (2021)

Aducanumab: Appropriate use recommendations
por: Cummings, Jeffrey, et al.
Publicado: (2021)

Aducanumab: Appropriate Use Recommendations
por: Cummings, J., et al.
Publicado: (2021)

Post-approval studies with the CFTR modulators Elexacaftor-Tezacaftor—Ivacaftor
por: Tümmler, Burkhard
Publicado: (2023)

Therapeutic Integrity of Microbiome-based Medicines in Neurodegenerative Disorders
por: Kumar, Dhiraj, et al.
Publicado: (2022)

Mechanistic insights into MARK4 inhibition by galantamine toward therapeutic targeting of Alzheimer’s disease
por: Adnan, Mohd, et al.
Publicado: (2023)

Flibanserin: Approval of a controversial drug for a controversial disorder
por: Sathyanarayana Rao, T. S., et al.
Publicado: (2015)

Identification of intrinsically disorder regions in non-structural proteins of SARS-CoV-2: New insights into drug and vaccine resistance
por: Anjum, Farah, et al.
Publicado: (2022)

Aducanumab: Appropriate Use Recommendations Update
por: Cummings, J., et al.
Publicado: (2022)

Practical Considerations in the Administration of Aducanumab for the Neurologist
por: Coerver, Katherine, et al.
Publicado: (2022)

Aducanumab—Hope or Disappointment for Alzheimer’s Disease
por: Wojtunik-Kulesza, Karolina, et al.
Publicado: (2023)

Computational Approaches for Supporting Combination Therapy in the Post-Aducanumab Era in Alzheimer’s Disease
por: Geerts, Hugo, et al.
Publicado: (2021)

Public opinion regarding U.S. Food and Drug Administration approval of aducanumab and potential policy responses: A nationally representative survey
por: DiStefano, Michael J., et al.
Publicado: (2022)

Clinical updates on tyrosine kinase inhibitors in HER2-positive breast cancer
por: Singh, Desh Deepak, et al.
Publicado: (2022)

Editorial: Molecular dynamics of cognitive-motor impairment in neurodegenerative diseases
por: Kumar, Dhiraj, et al.
Publicado: (2023)

Re: Aducanumab-Related ARIA: Paean or Lament?
por: Høilund-Carlsen, Poul F., et al.
Publicado: (2023)

B Cell Lymphoma 2: A Potential Therapeutic Target for Cancer Therapy
por: Alam, Manzar, et al.
Publicado: (2021)

Aducanumab, gantenerumab, BAN2401, and ALZ-801—the first wave of amyloid-targeting drugs for Alzheimer’s disease with potential for near term approval
por: Tolar, Martin, et al.
Publicado: (2020)

The Crux of the Medicine Prices' Controversy in Pakistan
por: Lee, Kah S., et al.
Publicado: (2017)

Insights into the Antibacterial Activity of Prolactin-Inducible Protein against the Standard and Environmental MDR Bacterial Strains
por: Yousuf, Mohd, et al.
Publicado: (2022)

Estimated Annual Spending on Aducanumab in the US Medicare Program
por: Mafi, John N., et al.
Publicado: (2022)

Role of Aducanumab in the Treatment of Alzheimer’s Disease: Challenges and Opportunities
por: Vaz, Miguel, et al.
Publicado: (2022)

Potential Therapeutic Implications of Caffeic Acid in Cancer Signaling: Past, Present, and Future
por: Alam, Manzar, et al.
Publicado: (2022)

Identification of Phytoconstituents as Potent Inhibitors of Casein Kinase-1 Alpha Using Virtual Screening and Molecular Dynamics Simulations
por: Shafie, Alaa, et al.
Publicado: (2021)

Rethinking the Appraisal and Approval of Drugs for Fracture Prevention
por: Erviti, Juan, et al.
Publicado: (2017)

Getting the Right Evidence After Drug Approval
por: Vreman, Rick A., et al.
Publicado: (2020)

Should Canadian patients look forward to aducanumab for Alzheimer disease?
por: Watt, Jennifer A., et al.
Publicado: (2021)

Aducanumab: a new phase in therapeutic development for Alzheimer’s disease?
por: Lalli, Giovanna, et al.
Publicado: (2021)

Aducanumab Therapy to Treat Alzheimer's Disease: A Narrative Review
por: Beshir, Semira Abdi, et al.
Publicado: (2022)

Aducanumab-Related Amyloid-Related Imaging Abnormalities: Paean or Lament?
por: Høilund-Carlsen, Poul F., et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_b1khv9itcss4jroddb5dk39fp6